1-3 of 3
Miklós Egyed, MD
Close
Sort by
Journal Articles

Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study.

Heinz Ludwig, MD, Zdenek Adam, MD, Roman Hajek, MD, Richard Greil, MD, Elena Tóthová, MD, Felix Keil, MD, Eva-Maria Autzinger, MD, Josef Thaler, MD, Heinz Gisslinger, MD, Alois Lang, MD, Miklós Egyed, MD, PhD, Niklas Zojer, MD
Journal: Blood
Blood (2009) 114 (22): 3862.
https://doi.org/10.1182/blood.V114.22.3862.3862
Published: 2009
Journal Articles

Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma.

Heinz Ludwig, MD, Zdenek Adam, MD, Elena Tóthová, MD, Roman Hajek, MD, Boris Labar, MD, PhD, Miklós Egyed, MD, PhD, Ivan Spicka, MD, Johannes Drach, MD, Heinz Gisslinger, MD, Ingrid Kuhn, MD, Niklas Zojer, MD, Zoran Birovljev, Axel Hinke, PhD
Journal: Blood
Blood (2009) 114 (22): 2891.
https://doi.org/10.1182/blood.V114.22.2891.2891
Published: 2009
Journal Articles

Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.

Heinz Ludwig, MD, Elena Tothova, MD, Roman Hajek, MD, Johannes Drach, MD, Zdenek Adam, MD, Boris Labar, MD, Miklós Egyed, MD, Ivan Spicka, MD, Heinz Gisslinger, MD, Ingrid Kuhn, MD, Axel Hinke, PhD
Journal: Blood
Blood (2007) 110 (11): 529.
https://doi.org/10.1182/blood.V110.11.529.529
Published: 2007